Die Suchmaschine für Unternehmensdaten in Europa

EU-Förderung (5.499.882 €): Impfstoffe und Infektionskrankheiten in der Alternden Bevölkerung Hor 01.01.2019 EU-Rahmenprogramm für Forschung und Innovation "Horizont"

Auf einen Blick

Text

Impfstoffe und Infektionskrankheiten in der Alternden Bevölkerung

Today’s major challenge is to improve efficacy of vaccines to protect the growing ageing population against infectious diseases (ID). The VITAL project aims to address this challenge by assessing the ID burden and mechanisms of immunosenescence to provide evidence-based knowledge on vaccination strategies to establish healthy ageing. Links with existing projects containing data sources combined with novel data acquired through our extensive network of data registries across Europe will result in a database of epidemiology, risk factors and burden of disease of both vaccine-preventable (VP) and potential vaccine-preventable ID. Crucial knowledge on factors that hamper immune responsiveness and in-depth analyses of immune compartments involved in inducing effective immune responses to different vaccines in the ageing host will be gathered. We will identify novel predictive, potentially universal immune profiles of vaccine responses using novel technologies, unique experimental models and (infection) cohorts of elderly subjects in which (bio)markers of frailty have already been identified. Novel strategies to address the problem of immunosenescence will be tested, in particular whether vaccination of middle-aged individuals can maintain proper memory immune responses in the elderly, to improve memory immunity before reaching old age. Using data on epidemiology of VPID and immune responsiveness, novel agent-based models will be developed to build a user- friendly tool to be used by health care professionals for optimal implementation of vaccination strategies for older people and to develop dissemination protocols for the obtained knowledge for the healthcare field. Finally, we will deliver a framework that forms the basis for designing, implementing and regularly updating vaccination schemes for the ageing population. Thereby, VITAL will initiate an important impetus to a more targeted immunization program for the elderly in Europe that will enhance healthy aging.


Geförderte Unternehmen:

Firmenname Förderungssumme
Academisch Ziekenhuis Groningen 690.000 €
Biomerieux SA 0,00 €
Centre National de la Recherche Scientifique CNRS 12.500,00 €
Federation Europeenne d'Associations et d'Industries Pharmaceutiques 0,00 €
Folkehelseinstituttet 248.473 €
Fundacion para El Fomento de La Investigacion Sanitaria y Biomedica de La Comunitat Valenciana 291.424 €
Glaxosmithkline Biologicals SA 0,00 €
Imperial College of Science Technology and Medicine 0,00 €
Institut National de la Sante et de la Recherche Medicale 230.000 €
Istituto Superiore Di Sanita 90.603 €
Janssen Vaccines & Prevention B.V. 0,00 €
Merck Sharp & Dohme Corp 0,00 €
Mihajlovic Jovan 60.000 €
P95 186.375 €
Pfizer Ltd. 0,00 €
Rijksinstituut Voor Volksgezondheid EN Milieu (Rivm) 1.919.535 €
Sanofi R&D Vaccins 0,00 €
Statens Serum Institut 206.936 €
Stichting European Clinical Research Alliance ON Infectious Diseases 10.000,00 €
Syreon Kutato Intezet kft. 255.976 €
Universita Degli Studi Di Ferrara 230.625 €
Universitaet Innsbruck 263.750 €
Universitair Medisch Centrum Utrecht 603.686 €
Universite Jean Monnet 200.000 €
University College London 0,00 €

Quelle: https://cordis.europa.eu/project/id/806776

Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider.